StreetInsider.com News Articles

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

Wed, 17 Jun 2026 07:00:00 -0400

Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹
Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³

ATLANTA, June 17, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the publication of two manuscripts in Brain Communications. One manuscript reports integrated safety and efficacy findings for KYGEVVI^® (doxecitine and doxribtimine), the first and only approved treatment for adults and pediatric patients with early-onset thymidine kinase 2 deficiency (TK2d) with a symptom onset on

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

Wed, 17 Jun 2026 07:00:00 -0400

Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹
Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

Wed, 17 Jun 2026 07:00:00 -0400

Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹
Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

Wed, 17 Jun 2026 07:00:00 -0400

Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹
Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

Wed, 17 Jun 2026 07:00:00 -0400

Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹
Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

Wed, 17 Jun 2026 07:00:00 -0400

Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹
Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

Wed, 17 Jun 2026 07:00:00 -0400

Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹
Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

Wed, 17 Jun 2026 07:00:00 -0400

Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹
Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

Wed, 17 Jun 2026 07:00:00 -0400

Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹
Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

Wed, 17 Jun 2026 07:00:00 -0400

Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹
Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

Wed, 17 Jun 2026 07:00:00 -0400

Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹
Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

Wed, 17 Jun 2026 07:00:00 -0400

Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹
Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

Wed, 17 Jun 2026 07:00:00 -0400

Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹
Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

Wed, 17 Jun 2026 07:00:00 -0400

Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹
Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³

Barclays Downgrades UCB (UCB:BB) (UCBJY) to Equalweight

Mon, 15 Jun 2026 01:38:21 -0400

Barclays analyst Charles Pitman downgraded UCB (UCB:BB) (OTC: UCBJY) from Overweight to Equalweight with a price target of EUR300.00 (from EUR310.00).

The analyst comments: “We update our forecasts for the recent better than-expected Bimzelx TRx trends and data, three 1H26 early-to-mid-stage acquisitions and FX, thus slightly raising our FY27/28/29 sales estimates, but our EBITDA forecasts reduce by L MSD% and our FY26-29 EPS CAGR reduces from 24.4% to 21.5%. Acknowledging that the company is clearly investing in its long-term growth and taking advantage of its net cash position, given the high-risk nature of the acquired assets, lack of near-term trial data

Barclays Downgrades UCB (UCB:BB) (UCBJY) to Equalweight

Mon, 15 Jun 2026 01:38:21 -0400

Barclays analyst Charles Pitman downgraded UCB (UCB:BB) (OTC: UCBJY) from Overweight to Equalweight with a price target of EUR300.00 (from EUR310.00).

Barclays Downgrades UCB (UCB:BB) (UCBJY) to Equalweight

Mon, 15 Jun 2026 01:38:21 -0400

Barclays analyst Charles Pitman downgraded UCB (UCB:BB) (OTC: UCBJY) from Overweight to Equalweight with a price target of EUR300.00 (from EUR310.00).

Barclays Downgrades UCB (UCB:BB) (UCBJY) to Equalweight

Mon, 15 Jun 2026 01:38:21 -0400

Barclays analyst Charles Pitman downgraded UCB (UCB:BB) (OTC: UCBJY) from Overweight to Equalweight with a price target of EUR300.00 (from EUR310.00).

Barclays Downgrades UCB (UCB:BB) (UCBJY) to Equalweight

Mon, 15 Jun 2026 01:38:21 -0400

Barclays analyst Charles Pitman downgraded UCB (UCB:BB) (OTC: UCBJY) from Overweight to Equalweight with a price target of EUR300.00 (from EUR310.00).

Barclays Downgrades UCB (UCB:BB) (UCBJY) to Equalweight

Mon, 15 Jun 2026 01:38:21 -0400

Barclays analyst Charles Pitman downgraded UCB (UCB:BB) (OTC: UCBJY) from Overweight to Equalweight with a price target of EUR300.00 (from EUR310.00).

UCB Launches Career-Advancing Scholarship Program for Adults Living with Hidradenitis Suppurativa and Immediate Family Members

Mon, 01 Jun 2026 11:11:00 -0400

Applications open June 1 for UCB's Hidradenitis Suppurativa Scholarship™ Program
Informed by patient insights, the initiative builds on UCB's network of scholarship programs in myasthenia gravis and epilepsy

ATLANTA, June 1, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the launch of the inaugural UCB Hidradenitis Suppurativa Scholarship™ Program, designed to support adults age 18 and older living with hidradenitis suppurativa (HS), and their immediate family members, in pursuing education and career development.

UCB Launches Career-Advancing Scholarship Program for Adults Living with Hidradenitis Suppurativa and Immediate Family Members

Mon, 01 Jun 2026 11:11:00 -0400

Applications open June 1 for UCB's Hidradenitis Suppurativa Scholarship™ Program
Informed by patient insights, the initiative builds on UCB's network of scholarship programs in myasthenia gravis and epilepsy

UCB Launches Career-Advancing Scholarship Program for Adults Living with Hidradenitis Suppurativa and Immediate Family Members

Mon, 01 Jun 2026 11:11:00 -0400

Applications open June 1 for UCB's Hidradenitis Suppurativa Scholarship™ Program
Informed by patient insights, the initiative builds on UCB's network of scholarship programs in myasthenia gravis and epilepsy

UCB Launches Career-Advancing Scholarship Program for Adults Living with Hidradenitis Suppurativa and Immediate Family Members

Mon, 01 Jun 2026 11:11:00 -0400

Applications open June 1 for UCB's Hidradenitis Suppurativa Scholarship™ Program
Informed by patient insights, the initiative builds on UCB's network of scholarship programs in myasthenia gravis and epilepsy

UCB Launches Career-Advancing Scholarship Program for Adults Living with Hidradenitis Suppurativa and Immediate Family Members

Mon, 01 Jun 2026 11:11:00 -0400

Applications open June 1 for UCB's Hidradenitis Suppurativa Scholarship™ Program
Informed by patient insights, the initiative builds on UCB's network of scholarship programs in myasthenia gravis and epilepsy